Alexandria Real Estate Eq... (ARE)

After a career that spanned two decades of experience at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.

ARE demonstrates resilience in a challenging life science real estate market, leveraging its mega-campus model and strong tenant relationships. Despite industry headwinds and high vacancy rates, ARE m...

Alexandria Real Estate Equities is rated a 'Buy' for its undervalued price, high 6.3% yield, and strong long-term prospects. ARE's mega-campus strategy, robust tenant base, and critical role in life s...

ARE and Lilly open Lilly Gateway Labs in San Diego, expanding biotech innovation with advanced labs and collaborative space.

Recent economic data has weakened market optimism. Gold has hit record highs, Treasury yields have fallen, and the dollar index continues to deteriorate as investors seek safety. Despite negative econ...

Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as un...

When it comes to dividend yields, bigger may not always be better.

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d...

REIT investors are attracted to high-yielding opportunities. But many of the highest-yielding REITs are risky. I highlight two popular high-yielding REITs to avoid.

Dividend stocks have long been a favorite for investors seeking both income and long-term growth. By combining regular cash payouts with potential stock appreciation, dividend-paying companies provide...